MannKind slides after halting late-stage trial for lung disease drug

MannKind

10/11/2025 15:20

** Shares of drugmaker MannKind MNKD.O fall as much as 7.5% to $5.2 after company halts late-stage trial for a type of lung disease treatment

** Shares hit a more than three-week low earlier in the session

** Co says its MNKD-101 drug, a nebulized version expected to treat nontuberculous mycobacterial (NTM) lung disease, shows no signs of treatment success in initial 46 patients

** The Data Safety Monitoring Board reviewed the interim data and agrees with co to discontinue the trial due to futility; no safety concerns were identified during the study

** MNKD to focus on MNKD-102, a dry powder inhalation formulation, still in early development, after its nebulized version failed to show effectiveness

** MNKD down 18% YTD

 (Reporting by Tharuniyaa Lakshmi in Bengaluru)

 ((tharuniyaa@thomsonreuters.com))